CDC holds CME activity on anthrax
The CME is based on information provided in an article published in the February issue of Emerging Infectious Diseases. The article describes how the CDC recently convened panels of anthrax experts to review and update guidelines for anthrax post exposure prophylaxis and treatment. For clinicians to obtain continuing medical education credit, they must read the article and answer a series of questions related to anthrax mortality risk, the preferred antimicrobial regimen for anthrax meningitis, treatments for patients with severe anthrax and post exposure prophylaxis for adults exposed to Bacillus anthracis.
According to the article, the panels included clinicians with experience treating anthrax patients and civilian and military anthrax experts. The panelists discussed recent patients with systemic anthrax, reviews of studies and data regarding antimicrobial drugs and anthrax antitoxins and critical care measures that could benefit anthrax patients.
The panels resulted in an update for antimicrobial and antitoxin treatment options and antimicrobial post exposure prophylaxis for individuals with anthrax. Changes from previous guidelines included additional antimicrobial choices and an expanded discussion of clinical and critical care procedures for anthrax.
Medscape LLC provides continuing medical education through courses certified by the Accreditation Council for Continuing Medical Education.
Anthrax is a serious infectious disease caused by the Bacillus anthracis bacterium. Anthrax can be found in soil and can infect humans if they come into contact with infected animals or contaminated animal products. The disease is more common in developing countries that do not have veterinary health programs that routinely vaccinate animals against anthrax.